Skip to content
Open in App
Corcept logo

Corcept

web2

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and de...

Symbol · 1CORT
Company profile

About

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig’s disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

ExchangeNasdaqPrimary symbol: 1CORT
ExchangeMilanPrimary symbol: 1CORT
Expert coverage

1 expert evaluated Corcept.

Orbitrum research

Experts evaluating Corcept

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment